overactive bladder

Small Doses: Pharmacy News Featuring Opioids, Ketamine, and More
Small Doses: Pharmacy News Featuring Opioids, Ketamine, and MoreSmall Doses is news for pharmacists in a way that works for you.
New Products: Neuromodulation system for OAB targets tibial nerveOther products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.
Brain activity in OAB patients characterized in studyPreliminary findings of a Swiss study revealed that the brain activity associated with the desire to void in response to the automated, repetitive filling and distention of the bladder with body warm saline differed greatly between healthy patients and patients with non-neurogenic overactive bladder.
Botulinum formulations show slight outcomes differencesA new comparative study showed that the use of intradetrusor injections of abobotulinum toxin A (Dysport) for urinary incontinence due to neurogenic detrusor overactivity provided results that were similar to or superior to those seen with onabotulinum toxin A (Botox), depending on the dosage of the latter.
Treatment of OAB may reduce fall risk in older patientsOveractive bladder (OAB) and falls often carry a substantial burden for patients and society as a whole, and new research suggests that treatment of OAB may lower fall risk. Learn more
PTNS efficacy bolstered by adjunctive pharmacotherapyStudy examines real-world effectiveness of percutaneous tibial nerve stimulation for treating overactive bladder.
CNS may be path to future voiding dysfunction therapiesIn this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for common voiding dysfunctions and future directions, including central nervous system agents and combination therapies.
Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCaOther pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.
Uro Pipeline: IDE approval granted for implantable neurostimulatorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Neuromodulation adverse events characterizedResearchers recently presented 12-month follow-up data from a prospective, multicenter trial of a device for sacral neuromodulation.